x.com· @ · X·· 2026-04-22Score60
Reading
Next-generation ADCs: payload innovation
Body
@jonchou05 delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder cancer. @UCSFCancer
#AACR26
The takeaways: https://t.co/9VhkyZ4etc
Heat 19 · 13 likes · 0 replies · 6 reposts
Conference abstracts
1729matched by 药名 enfortumab
OBI-904, a next-generation nectin-4-targeting exatecan ADC, demonstrates enhanced cytotoxicity and overcomes enfortumab vedotin resistanceYuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen
Read the abstract →2958matched by 药名 enfortumab
P-glycoprotein (ABCB1) overexpression confers resistance to the antibody-drug conjugate Enfortumab vedotin in EV-resistant organoid and PDX models.Emilie Decaup, Claire Béraud, Isabelle Bernard-Pierrot, Guerric Gilbert, Clémentine Krucker, Xavier Gamé, Philippe Lluel, Nadège Bidan
Read the abstract →Abraham R. Meyerson, Daniel V. Rodriguez, Fengshen Kuo, Sanaz Firouzi, Sadna Budhu, Kwanghee Kim, Jonathan Coleman
Read the abstract →Source: x.com · x.com